FGFR4 ASO dose-dependently reduced FGFR4 expression, and lowered adiposity and increased whole body metabolic rate.

<p>DIO mice were treated with saline, control (Cont) ASO or FGFR4 ASO #1 at 25, 50, or 75 mg/kg/week for 13 weeks; a group of lean mice treated with saline was used as normal controls. (A) Upper panel, representative Western blots of liver FGFR4 protein and SRB1 protein (as loading control); lower panel, the quantitative values of liver FGFR4 protein after normalizing to SRB1. (B) Cumulative food intake during the treatment. (C) BW changes during the treatment. (D) Total body fat content at different time points of the treatment. (E) Fat depot weights at the end of the treatment. (F) Plasma β-hydroxybutyrate (3HB) levels at week 0 and week 12. (G) Whole body O₂ consumption rate (VO₂). Data are expressed as mean ± SEM (n = 6–9/group). *<i>P</i><0.05 and **<i>P</i><0.01 vs. saline controls, or as indicated in the figure; ^#<i>P</i><0.05 and ^##<i>P</i><0.01 vs. Cont ASO; NS, not significant.